Market Herald logo

Subscribe

Be the first with the news that moves the market
  • FSD Pharma (HUGE) is sharing pre-clinical data demonstrating the potentially disease-modifying effects of its lead drug candidate Lucid-MS in mice
  • The company has released a video explaining its pre-clinical results, including visual evidence of functional recovery on pre-clinical subjects
  • Anthony Durkacz, interim CEO at FSD Pharma sat down with Caroline Egan to discuss the drug candidate and the exciting results demonstrated in the video
  • FSD Pharma is a biotechnology company with three drug candidates in different stages of development
  • FSD Pharma Inc. (HUGE) opened trading at C$1.45 per share

FSD Pharma (HUGE) is sharing pre-clinical data demonstrating the potentially disease-modifying effects of its lead drug candidate Lucid-MS.

Lucid-MS is the company’s lead drug candidate for the potential treatment of multiple sclerosis (MS).

Anthony Durkacz, interim CEO at FSD Pharma sat down with Caroline Egan to discuss Lucid-MS and the exciting visual evidence shown in this video.

FSD Pharma is also advancing the development of its other drug candidates, including Lucid-PSYCH, a psychoactive molecule targeted to treat Major Depressive Disorder, and FSD-PEA, an anti-inflammatory compound.

FSD Pharma is a biotechnology company with three drug candidates in different stages of development. Through the company’s wholly-owned subsidiary, Lucid, FSD Pharma is also focused on the research and development of its lead compounds, Lucid-PSYCH (formerly Lucid-201) and Lucid-MS (formerly Lucid-21-302). Lucid PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders.

FSD Pharma Inc. (HUGE) opened trading at C$1.45 per share.

More From The Market Herald

" Medicenna (TSX:MDNA) announces publication of MDNA11 preclinical data

Medicenna Therapeutics Corp. (MDNA) announced the publication of preclinical data on MDNA11.
The Market Herald Video

" Avrupa Minerals (TSXV:AVU) reports new drill results at the Sesmarias Prospect

Avrupa Minerals (AVU) reports that drilling continues at the Sesmarias Copper-Zinc Prospect within the Alvalade Project in Portugal.
The Market Herald Video

" Nextech AR (CSE:NTAR) (OTCQB:NEXCF) closes private placement and joins Khronos Group

Nextech AR (NTAR) has closed its previously announced capital raise and joined the Khronos Group as a contributor member.
The Market Herald Video

" QuestEx (TSXV:QEX) expands gold mineralization at Inel Prospect

QuestEx (QEX) has announced drill and prospecting results from the Inel Gold Prospect in B.C.